SAVA Company Profile and Key Details
Cassava Sciences, Inc.
SAVA Stock Price Chart
Stock Price Today
Cassava Sciences, Inc. (SAVA) stock declined over -4.73%, trading at $2.62 on NASDAQ, down from the previous close of $2.75. The stock opened at $2.76, fluctuating between $2.61 and $2.77 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Company Information
| Employees | 29 |
| Beta | -0.58 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Cassava Sciences, Inc. (NASDAQ: SAVA) stock price is $2.62 in the last trading session. During the trading session, SAVA stock reached the peak price of $2.77 while $2.61 was the lowest point it dropped to. The percentage change in SAVA stock occurred in the recent session was -4.73% while the dollar amount for the price change in SAVA stock was -$0.13.
The NASDAQ listed SAVA is part of Biotechnology industry that operates in the broader Healthcare sector. Cassava Sciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. R. Christopher Cook
Senior Vice President & Gen. Counsel
Dr. James W. Kupiec M.D.
Chief Medical Officer
Mr. Michael Zamloot
Senior Vice President of Technical Operations
Mr. Remi Barbier
Founder, Chairman, Pres & Chief Executive Officer
Dr. Nadav Friedmann M.D., Ph.D.
Chief Medical Officer & Director
Dr. Lindsay H. Burns Ph.D.
Senior Vice President of Neuroscience
Dr. George Thornton
Senior Vice President of Technology
Dr. Michael Marsman Pharm.D.
Senior Vice President of Regulatory Affairs
Mr. Eric J. Schoen
Chief Financial Officer
SAVA's closing price is 17.49% higher than its 52-week low of $2.23 where as its distance from 52-week high of $42.20 is -93.79%.
Number of SAVA employees currently stands at 29.
Official Website of SAVA is: https://www.cassavasciences.com
SAVA could be contacted at phone 512 501 2444 and can also be accessed through its website. SAVA operates from 7801 North Capital of Texas Highway, Austin, TX 78731, United States.
SAVA stock volume for the day was 1.54M shares. The average number of SAVA shares traded daily for last 3 months was 5.72M.
The market value of SAVA currently stands at $126.05M with its latest stock price at $2.62 and 48.11M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com